Application of Advate® for the treatment of patients with hemophilia A

Aim. A retrospective study of the efficacy and safety of the use of the Advate® (Oсtoсog alpha) factor VIII (FVIII) drug for the preventive treatment and reduction of acute bleeding episodes in patients with hemophilia A living in the Amur Region. Materials and methods. A retrospective observational monocentric initiative study of the results of the use of the Advate® was performed, which was carried out as part of routine clinical practice (2017-2019). Two comparison groups were formed; each included 14 patients with severe and moderate forms of hemophilia. Each group consists of 2 subgroups: A – 5 patients over the age of 18 years with hemophilic arthropathy, receiving tertiary prophylaxis (1A – with the Advate and 2A – with other foreign drugs FVIII); B – 9 patients under the age of 18 years, without signs of irreversible joint damage, receiving primary and secondary prophylaxis (1B – with Advate and 2B with other foreign drugs FVIII). The work used the results of an individual interview and clinical examination of patients with hemophilia A, data from outpatient records and diaries kept by patients or their parents and in which certain events were recorded during the period of prophylactic treatment with coagulation factor VIII (FVIII) drugs. Results. As a result of the study, data were obtained that the Advate during both prophylactic therapy and reduction of acute bleeding is not inferior in effectiveness to other FVIII concentrates. In patients of subgroup 1A (with the presence of hemophilic arthropathy), it was possible to reduce the frequency of bleeding compared to the period when these patients received therapy “on demand” by 97%, which corresponds to patients from subgroup 2A. Preventive therapy with commercial FVIII drugs, including Advate, started in childhood, made it possible to avoid severe, life-threatening options for bleeding and the development of orthopedic pathology. Advate therapy for patients with hemophilia A was not accompanied by the development of toxic, thrombogenic and immunogenic reactions. Conclusion. Advate® can be effectively used for the prevention and reduction of acute bleeding in patients with hemophilia.

hemophilia A, hemorrhagic syndrome, preventive treatment, Advate

1. Zozulya N.I., Kumskova M.A. The protocol for the diagnosis and treatment of hemophilia. In: Algorithms for the diagnosis and treatment of diseases of the blood system / ed. V.G.Savchenko. Moscow: Praktika; 2018 (Vol.1):333–358 (in Russian). ISBN 978-5-89816-164-4

2. Mamaev A.N. Coagulopathy. Moscow: GEOTAR-Media; 2012 (in Russian). ISBN: 978-5-9704-2099-7

3. Andreev Yu.N. Many-sided hemophilia. Moscow: N'yudiamed; 2006 (in Russian). ISBN: 5-88107-041-0

4. Barkagan Z.S. Hereditary disorders of coagulation hemostasis. Guide to hematology, 3rd edition / ed. A.I.Vorobʹev. Moscow: N'yudiamed; 2005 (Vol.3):45–73 (in Russian).

5. Zozulya N.I. Hemophilia a therapy – from the past to the present day. Lechenie i profilaktika 2019; 9(4):72–78 (in Russian).

6. Colvin B.T., Astermark J., Fischer K., Gringeri A., Lassila R., Schramm W., Thomas A., Ingerslev J.; Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14(2):361–74. doi: 10.1111/j.1365-2516.2007.01625.x

7. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., Key N.S., Kitchen S., Llinas A., Ludlam C.A., Mahlangu J.N., Mulder K., Poon M.C., Street A. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1):1–47. doi: 10.1111/j.1365-2516.2012.02909.x

8. Vorobev A.I.,Plyushch O.P., Barkagan Z.S., Andreev Yu.N., Buevich E.I., Kopylov K.G., Vdovin V.V., Svirin P.V., Vorobev P.A., Lukyantseva D.V. Protocol for patients' management "Hemophilia". Problemy stsndartizatsii v zdravookhranenii 2006; 3:18–74 (in Russian).

9. Fischer K., Van der Bom J.G., Mauser-Bunschoten E.P., Roosendaal G., Prejs R., De Kleijn P., Grobbee D.E., Van den Berg M. The Effects of Postponing Prophylactic Treatment on Long-Term Outcome in Patients With Severe Hemophilia. Blood 2002; 99(7):2337–2341. doi: 10.1182/blood.v99.7.2337

10. Fischer K., Astermark J., van der Bom J.G., Ljung R., Berntorp E., Grobbee D.E., van den Berg H.M. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8(6):753–760. doi: 10.1046/j.1365-2516.2002.00694.x

11. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., Riske B., Hacker M.R., Kilcoyne R., Ingram J.D., MancoJohnson M.L., Funk S., Jacobson L., Valentino L.A., Hoots W.K., Buchanan G.R., DiMichele D., Recht M., Brown D., Leissinger C., Bleak S., Cohen A., Mathew P., Matsunaga A., Medeiros D., Nugent D., Thomas G.A., Thompson A.A., McRedmond K., Soucie J.M., Austin H., Evatt B.L. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. N. Engl. J. Med. 2007; 357(6):535–544. doi: 10.1056/NEJMoa067659

12. Collins P.W., Bjorkman S., Fischer K., Blanchette V.S., Oh M., Schroth P., Fritsch S., Casey K., Spotts G., Ewenstein B.M. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J. Thromb. Haemost. 2010; 8(2):269–275. doi: 10.1111/j.1538-7836.2009.03703.x

13. De Moerloose P., Fischer K., Lambert T., Windyga J., Batorova A., Lavigne-Lissalde G., Rocino A., Astermark J., Hermans C. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18(3):319–325. doi: 10.1111/j.1365-2516.2011.02671.x

14. Khair K., Mazzucconi M.G., Parra R., Santagostino E., Tsakiris D.A., Hermans C., Oldenburg J., Spotts G., Steinitz-Trost K., Gringeri A. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year followup of the AHEAD (Advate in HaEmophilia A outcome Database). Haemophilia 2018; 24(1):85–96. doi: 10.1111/hae.13361

15. Voitsekhovsky V.V., Zabolotskikh T.V., Esenina T.V., Suslova Yu.V. Individual therapy of patients with hemophilia. In: The 15th Sino-Russia Forum of Biomedical and Pharmaceutical Science. The conference proceedings. Harbin: Heilongjiang University of Chinese Medicine; 2018. рр.1–2.